Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A Mittendorf , Zhang Hong , Carlos H Barrios , Shigehira Saji , Kyung Hae Jung , Roberto Hegg , Andreas Koehler , Joohyuk Sohn , Hiroji Iwata , Melinda L Telli , Cristiano Ferrario , Kevin Punie , Frédérique Penault Llorca (1, 2) , Shilpen Patel , Duc Anh Nguyen , Mario Liste-Hermoso , Vidya Maiya , Luciana Molinero , Stephen y Chui , Nadia Harbeck

1 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
2 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]

Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 compared efficacy and safety of atezolizumab versus placebo combined with nab-paclitaxel followed by doxorubicin plus cyclophosphamide as neoadjuvant treatment for early-stage TNBC.

F Hoffmann-La Roche/Genentech.

Domaines: Sciences du Vivant [q-bio]

Elizabeth A Mittendorf, Zhang Hong, Carlos H Barrios, Shigehira Saji, Kyung Hae Jung, et al.. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. The Lancet, 2020, 396 (10257), pp.1090-1100. ⟨10.1016/S0140-6736(20)31953-X⟩. ⟨hal-03046446⟩